MSB -17%: crashed to 18 month lows today after Swiss healthcare giant Novartis walked from a deal around a treatment for COVID related respiratory issues. Novartis and Mesoblast penned a collaboration agreement last year which saw Novartis make an initial $US50m upfront payment with a $US25m equity stake. The deal could have been worth $US1.25b the remestemcel-L treatment was to achieve certain commercialisation targets and sales milestones but Novartis pulled the plug today, around 12 months after the initial day. Mesoblast remains confident the treatment is effective and trials have shown a fall in mortality rates in trials on COVID ARDS patients.
scroll
PULSE CHECK WEBINAR: Portfolio positioning towards FY26
Close
Vaneck FTSE Global Infrastructure ETF (IFRA)
Close
Gerrish: The correction is done, we’re positioning for what comes next
Close
Friday 6th June – Dow off -108pts, SPI down -13pts
Close
Relevant suggested news and content from the site
Video
WATCH
PULSE CHECK WEBINAR: Portfolio positioning towards FY26
FY26 is shaping up as a year where strategic portfolio positioning will matter more than ever. Hear from James Gerrish & Shawn Hickman as they detail MM's current views.
chart
Vaneck FTSE Global Infrastructure ETF (IFRA)
Video
WATCH
Gerrish: The correction is done, we’re positioning for what comes next
The Market Matters lead portfolio manager talks the recent recovery, Trump, gold, and why he thinks there's plenty of opportunities.
Podcast
LISTEN
Friday 6th June – Dow off -108pts, SPI down -13pts
Daily Podcast Direct from the Desk
Members only
UNLOCK MARKET MATTERS NOW
Take a free trial.
No payment details required.
